These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 29741296)

  • 1. Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: Position statement of the Endocrine Society of Australia, the Australian and New Zealand Bone & Mineral Society, the Australasian Menopause Society and the Clinical Oncology Society of Australia.
    Grossmann M; Ramchand SK; Milat F; Vincent A; Lim E; Kotowicz MA; Hicks J; Teede H
    Clin Endocrinol (Oxf); 2018 Sep; 89(3):280-296. PubMed ID: 29741296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: position statement summary.
    Grossmann M; Ramchand SK; Milat F; Vincent A; Lim E; Kotowicz MA; Hicks J; Teede HJ
    Med J Aust; 2019 Sep; 211(5):224-229. PubMed ID: 31318068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of adjuvant endocrine therapy on bone health in women with breast cancer.
    Ramchand SK; Cheung YM; Yeo B; Grossmann M
    J Endocrinol; 2019 Jun; 241(3):R111-R124. PubMed ID: 30991355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone health in women with breast cancer.
    Ramchand SK; Cheung YM; Grossmann M
    Climacteric; 2019 Dec; 22(6):589-595. PubMed ID: 30896255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
    Reid DM; Doughty J; Eastell R; Heys SD; Howell A; McCloskey EV; Powles T; Selby P; Coleman RE
    Cancer Treat Rev; 2008; 34 Suppl 1():S3-18. PubMed ID: 18515009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.
    Gnant M; Pfeiler G; Dubsky PC; Hubalek M; Greil R; Jakesz R; Wette V; Balic M; Haslbauer F; Melbinger E; Bjelic-Radisic V; Artner-Matuschek S; Fitzal F; Marth C; Sevelda P; Mlineritsch B; Steger GG; Manfreda D; Exner R; Egle D; Bergh J; Kainberger F; Talbot S; Warner D; Fesl C; Singer CF;
    Lancet; 2015 Aug; 386(9992):433-43. PubMed ID: 26040499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteoporosis management in patients with breast cancer: EMAS position statement.
    Trémollieres FA; Ceausu I; Depypere H; Lambrinoudaki I; Mueck A; Pérez-López FR; van der Schouw YT; Senturk LM; Simoncini T; Stevenson JC; Stute P; Rees M
    Maturitas; 2017 Jan; 95():65-71. PubMed ID: 27802892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer Treatment-Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy.
    Diana A; Carlino F; Giunta EF; Franzese E; Guerrera LP; Di Lauro V; Ciardiello F; Daniele B; Orditura M
    Curr Treat Options Oncol; 2021 Apr; 22(5):45. PubMed ID: 33864145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer.
    Waqas K; Lima Ferreira J; Tsourdi E; Body JJ; Hadji P; Zillikens MC
    J Bone Oncol; 2021 Jun; 28():100355. PubMed ID: 33948427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of bone health in women with estrogen receptor-positive breast cancer receiving endocrine therapy.
    Malagrinò M; Zavatta G
    Womens Health (Lond); 2023; 19():17455057221149493. PubMed ID: 36644991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Options for the Management of Aromatase Inhibitor- Associated Bone Loss.
    Gaudio A; Xourafa A; Rapisarda R; Castellino P
    Endocr Metab Immune Disord Drug Targets; 2022; 22(3):259-273. PubMed ID: 34370654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of bone loss in postmenopausal breast cancer patients treated with aromatase inhibitors.
    Cepa M; Vaz C
    Acta Reumatol Port; 2015; 40(4):323-30. PubMed ID: 26922195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skeletal health in breast cancer survivors.
    Bruyère O; Bergmann P; Cavalier E; Gielen E; Goemaere S; Kaufman JM; Rozenberg S; Body JJ
    Maturitas; 2017 Nov; 105():78-82. PubMed ID: 28838807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
    Brufsky A
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical review: Effect of endocrine therapies on bone in breast cancer patients.
    Santen RJ
    J Clin Endocrinol Metab; 2011 Feb; 96(2):308-19. PubMed ID: 21147884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of dual-energy X-ray absorptiometry plus antiresorptive treatment in Australian women with breast cancer who receive aromatase inhibitors.
    Sowa PM; Downes MJ; Gordon LG
    J Bone Miner Metab; 2017 Mar; 35(2):199-208. PubMed ID: 26969395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aromatase inhibitors and bone health.
    Bundred NJ
    Curr Opin Obstet Gynecol; 2009 Feb; 21(1):60-7. PubMed ID: 19125005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention?
    Hadji P; Gnant M; Body JJ; Bundred NJ; Brufsky A; Coleman RE; Guise TA; Lipton A; Aapro MS
    Cancer Treat Rev; 2012 Oct; 38(6):798-806. PubMed ID: 22429722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recommendations for antiresorptive therapy in postmenopausal patients with breast cancer: Marburg AIBL Guideline Evaluation Study (MAGES).
    Hadji P; Hartenfels M; Kyvernitakis J; Hars O; Baumann KH; Kalder M
    Breast Cancer Res Treat; 2012 Jun; 133(3):1089-96. PubMed ID: 22453753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone health during endocrine therapy for cancer.
    Rachner TD; Coleman R; Hadji P; Hofbauer LC
    Lancet Diabetes Endocrinol; 2018 Nov; 6(11):901-910. PubMed ID: 29572126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.